8-K: Akebia Therapeutics Extends Supply Agreement with STA Pharmaceutical Through 2032

Akebia Therapeutics has extended its supply agreement with STA Pharmaceutical for vadadustat drug product until January 1, 2032, and amended the pricing structure.

Summary

• Akebia Therapeutics has amended its supply agreement with STA Pharmaceutical Hong Kong Limited.
• The amendment extends the term of the supply agreement to January 1, 2032.
• The amendment also modifies the volume-based pricing structure for vadadustat drug product.
• Other provisions related to the product under the supply agreement have also been amended.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the extension of the supply agreement provides stability and long-term planning for Akebia. However, the lack of specific financial details prevents a higher score.

Positives

• The extension of the supply agreement provides long-term certainty for the supply of vadadustat.
• The amended pricing structure could potentially lead to more favorable terms for Akebia.

Risks

• The specific details of the amended pricing structure are not disclosed, making it difficult to assess the financial impact.
• The reliance on a single supplier, STA, for vadadustat could pose a risk if STA encounters any issues.

Future Outlook

The company expects to file a copy of the amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly in the context of supply chain management and long-term agreements for drug manufacturing. It indicates Akebia's commitment to securing a stable supply of its key product, vadadustat.

Comparison to Industry Standards

• Long-term supply agreements are common in the pharmaceutical industry to ensure consistent production and supply of drugs.
• Companies like Amgen and Gilead often enter into similar agreements with contract manufacturing organizations (CMOs) to manage their supply chains.
• The specific terms of pricing structures vary widely based on volume, exclusivity, and other factors, making direct comparisons difficult without more details.

Stakeholder Impact

• Shareholders may view the extended supply agreement positively as it ensures the continued availability of vadadustat.
• The agreement provides certainty for Akebia's operations and supply chain.

Next Steps

• Akebia will file the amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024.

Key Dates

Keywords

Akebia Therapeutics, STA Pharmaceutical, vadadustat, supply agreement, contract extension, pricing structure, pharmaceuticals